Skip to content

Remifentanil for Preventing Propofol Injection Pain in Elderly Patients

Effect-site Concentration of Remifentanil for Preventing Propofol Injection Pain in Elderly Patients: A Comparison With Adult Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03330782
Enrollment
52
Registered
2017-11-06
Start date
2017-11-16
Completion date
2018-06-15
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Usage

Keywords

pain, propofol, remifentanil

Brief summary

Elderly patients show different pharmacokinetic and pharmacodynamic variables and usually need smaller doses of anesthetic drugs than younger patients. The purpose of this study was to investigate the optimal effect-site concentration of remifentanil for preventing injection pain during propofol induction in elderly patients by the Dixon's up-and-down method.

Interventions

DRUGRemifentanil

Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)

Sponsors

Ajou University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* ASA physical status I or II undergoing general anesthesia

Exclusion criteria

* neurologic disorder * psychologic disorder * vascular disorder * patients with chronic pain * difficulty in vascular access

Design outcomes

Primary

MeasureTime frameDescription
Severity of propofol injection pain-4 point scaleduring 3 min after remifentanil and propofol infusion to reach the equilibrium of plasma and effect-site concentration0 = no pain (negative response to questioning), 1. = mild pain (pain reported only in response to questioning without any behavioral signs), 2. = moderate pain (pain reported in response to questioning and accompanied by a behavioral signs or pain reported spontane¬ously without questioning), 3. = severe pain (vocal response accompanied by facial grimacing, arm withdrawal, or tears)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026